Clinical Trials Logo
  1. Home
  2. Hepatobiliary Neoplasm
  3. NCT04010071

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Biliary Tract Neoplasms Clinical Trial

Official title:
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial

Clinical Trial Summary

The investigators design a phase II clinical study to explore the efficacy and safety of axitinib plus toripalimab as a second-line treatment in patients with hepatobiliary malignant tumors and to analyze potential biomarkers of therapeutic response.

Clinical Trial Description

This phase II trial is a single-arm, non-randomized and single-center clinical study. It is estimated that 60 patients who met the study criteria will be enrolled in PUMCH and treated with axitinib plus toripalimab. The investigators will follow up and collect subjects' data each month to evaluate the efficacy and safety of treatment, including overall survival and time to progression, until disease progression or death. Histopathology and multi-omics data analysis will be used to explore potential biomarkers of treatment response. Study Type: Interventional. Masking: Open Label. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04010071
Study type Interventional
Source Peking Union Medical College Hospital
Contact Xiaobo Yang, MD
Phone 010-69156043
Email jzlin816@126.com
Status Recruiting
Phase Phase 2
Start date May 1, 2020
Completion date June 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Completed NCT03101566 - Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Phase 2
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Not yet recruiting NCT06037655 - Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC Phase 2
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT00196105 - Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) N/A
Completed NCT02558959 - Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer Phase 2
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Completed NCT02784353 - Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy N/A
Recruiting NCT05429203 - Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope N/A
Recruiting NCT02255669 - Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction N/A
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Completed NCT00422409 - Endoscopic Stenting of Gastrointestinal Cancer N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03063554 - EUS BD vs ERCP TP for Pancreatic Cancer N/A
Terminated NCT02615210 - Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures N/A
Completed NCT04595058 - LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent N/A
Recruiting NCT04856761 - A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Recruiting NCT03427242 - Apatinib for Advanced Biliary Carcinoma Phase 2
Recruiting NCT05615818 - Personalized Medicine for Advanced Biliary Cancer Patients Phase 3